Bruker Introduces Routine Gradient Spectroscopy & Robust, Industry-Standard PAL® Automation on High-Performance Fourier™ 8...
October 19 2020 - 6:00AM
Business Wire
Bruker Corporation (Nasdaq: BRKR) announces the European launch
of the high-performance Fourier™ 80 system, a
next-generation, 80 MHz Fourier Transform Nuclear Magnetic
Resonance (FT-NMR) benchtop spectrometer, now with major new
capabilities.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201019005105/en/
The new Fourier 80 brings the power of
NMR to the bench. (Photo: Business Wire)
The Fourier 80 now is routinely equipped for gradient
spectroscopy and offers the option of an industry-standard CTC PAL®
sample changer. The Fourier 80 is suitable for organic or
medicinal chemistry analysis, NMR teaching, synthesis verification
or routine analysis in any chemistry laboratory. Equipped with a
novel, ultra-stable 80 MHz permanent magnet, it requires no
cryogens, water cooling, or special lab infrastructure.
The Fourier 80 has been designed for highest data quality
and stability at 80 MHz, with excellent line-shape, resolution and
sensitivity in 80 MHz homonuclear 1H or heteronuclear 1H/13C FT-NMR
experiments. The latest version now offers even greater sensitivity
and 20% improved resolution performance. It can be operated by the
easy-to-use GoScan™ software for NMR beginners, or by
Bruker's TopSpin™ NMR software with the extensive
TopSpin library of 1D and 2D homonuclear and proton-carbon
heteronuclear experiments and pulse programs.
The latest version of the Fourier 80 now includes a
pulsed field gradient which has been used in high-field NMR
spectroscopy for decades to quickly and conveniently obtain
essentially artifact-free spectra. Gradients allow users to enhance
solvent or water suppression, perform DOSY experiments, and acquire
two-dimensional NMR spectra within minimal experiment time.
Another new feature is the option of an industry-standard,
robust and high-throughput PAL sample changer. Fourier
80 users with the PAL sample changer can run up to 132 samples,
including 12 reference samples, thereby dramatically increasing
throughput and efficiency. GoScan now also operates the
sample changer to run samples overnight or over a weekend.
The Fourier 80 offers workflows and protocols for
academic, pharma and industrial chemistry research, as well as for
forensics and organic synthesis control. It can be incorporated
into science education to introduce students to the power of
FT-NMR. An optional teaching package with recommended experiments
and spectra interpretation guide is also available.
Dr. Falko Busse, President of the Bruker BioSpin Group,
commented: "Bruker is proud to offer the Fourier 80 with
new, industry-leading capabilities like routine gradient
spectroscopy, and a robust, well-accepted PAL sample changer.
High-performance 80 MHz FT-NMR can now be used efficiently in any
chemistry lab, just like benchtop mass spectrometers or FT-IR
systems which have proliferated in chemistry labs for decades. The
Fourier 80 is providing education packages to give
instructors tools to introduce young scientists to the power of
FT-NMR. With the Fourier 80, we further 'democratize' the
many applications of NMR."
Join the launch of the Fourier 80 starting on October
19th at www.bruker.com/Fourier80. Watch exclusive content
describing the new capabilities and hear from experts. Visitors
will be able to ask questions and interact with members of the
Bruker NMR team.
® PAL is a registered trademark of CTC Analytics AG
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201019005105/en/
Investor Contact: Miroslava Minkova Director, Investor
Relations & Corporate Development T: +1 (978) 663-3660 x1479 E:
Investor.Relations@bruker.com
Media Contact: Thorsten Thiel, Ph.D. VP of Group
Marketing Bruker BioSpin T: +49 (721) 5161–6500 E:
thorsten.thiel@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024